Literature DB >> 26175348

Potentially inappropriate prescribing detected by STOPP-START criteria: are they really inappropriate?

Isabel Lozano-Montoya1, Manuel Vélez-Diaz-Pallarés2, Eva Delgado-Silveira2, Beatriz Montero-Errasquin1, Alfonso Jose Cruz Jentoft1.   

Abstract

BACKGROUND: the STOPP-START criteria were developed to detect potentially inappropriate prescribing (PIP) in older people. The reasons why multidisciplinary geriatric teams decide not to follow STOPP-START criteria have not been studied.
OBJECTIVE: to analyse compliance with the recommendations of the STOPP-START criteria in older inpatients.
DESIGN: ambispective, non-randomised study. SUBJECTS
SETTING: three hundred and eighty-eight consecutive patients aged 80 years or over admitted to the acute geriatric medicine unit of a University hospital.
METHODS: STOPP-START criteria were systematically used by a pharmacist to assess pre-admission treatments, and the multidisciplinary geriatric team decided what drugs were recommended after discharge. Two researches independently assessed how many STOPP-START recommendations were accepted by the team, and if they were not accepted, why.
RESULTS: two hundred and eighty-four PIPs were identified (0.8 per subject) according to STOPP criteria. Two hundred and forty-seven of these prescriptions (87.0%) were discontinued at discharge. STOPP recommendations were not accepted in 37 cases, mostly because the team considered other therapeutic priorities (lorazepam, n = 12; risperidone, n = 5; other, n = 18). Three hundred and ninety-seven PIPs were identified according to START criteria (1.1 per subject). START recommendations were not followed at discharge in 264 cases (66.5%). The most frequent reasons were as follows: severe disability (n = 90), the use of other effective treatments for the condition (n = 38) and high risk of severe adverse effects (n = 32). Not following START criteria was significantly associated with dependency for basic activities of daily living (ADLs) (odds ratio, OR: 0.66 for compliance with a recommendation; 0.49-0.89), dependency for instrumental ADLs (OR: 0.64; 0.48-0.85) or inability to walk (OR: 0.72; 0.54-0.98).
CONCLUSIONS: potentially inappropriate drugs are usually discontinued, but many older hospitalised patients do not receive potentially recommended medications. More research on the reasons and consequences of this fact is needed.
© The Author 2015. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  STOPP/START; older people; potentially inappropriate prescribing

Mesh:

Year:  2015        PMID: 26175348     DOI: 10.1093/ageing/afv079

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  11 in total

1.  Potentially inappropriate prescribing and associated factors in elderly patients at hospital discharge in Brazil: a cross-sectional study.

Authors:  Ana Luiza Pereira Moreira Mori; Renata Cunha Carvalho; Patricia Melo Aguiar; Maria Goretti Farias de Lima; Magali da Silva Pacheco Nobre Rossi; José Fernando Salvador Carrillo; Egídio Lima Dórea; Sílvia Storpirtis
Journal:  Int J Clin Pharm       Date:  2017-02-10

2.  Effect of a Pharmacist-Driven Medication Management Intervention Among Older Adults in an Inpatient Setting.

Authors:  Sara Alosaimy; Alka Vaidya; Kevin Day; Gretchen Stern
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

3.  Medication Appropriateness in Vulnerable Older Adults: Healthy Skepticism of Appropriate Polypharmacy.

Authors:  Terri R Fried; Marcia C Mecca
Journal:  J Am Geriatr Soc       Date:  2019-01-30       Impact factor: 5.562

Review 4.  Medication review in hospitalised patients to reduce morbidity and mortality.

Authors:  Mikkel Christensen; Andreas Lundh
Journal:  Cochrane Database Syst Rev       Date:  2016-02-20

5.  Assessment of the Appropriateness of Prescriptions in a Geriatric Outpatient Clinic

Authors:  Burcu Kelleci Çakır; Muhammet Cemal Kızılarslanoğlu; Mustafa Kemal Kılıç; Rana Tuna Doğrul; Mehmet Emin Kuyumcu; Aygin Bayraktar Ekincioğlu; Merve Başol; Meltem Halil; Kutay Demirkan
Journal:  Turk J Pharm Sci       Date:  2022-02-28

6.  Relationship between frailty, polypharmacy, and underprescription in older adults living in nursing homes.

Authors:  Marta Gutiérrez-Valencia; Mikel Izquierdo; Esther Lacalle-Fabo; Itxaso Marín-Epelde; María Fernanda Ramón-Espinoza; Thamara Domene-Domene; Álvaro Casas-Herrero; Arkaitz Galbete; Nicolás Martínez-Velilla
Journal:  Eur J Clin Pharmacol       Date:  2018-03-27       Impact factor: 2.953

7.  Assessing Potentially Inappropriate Prescribing in Community-Dwelling Older Patients Using the Updated Version of STOPP-START Criteria: A Comparison of Profiles and Prevalences with Respect to the Original Version.

Authors:  Encarnación Blanco-Reina; Maria Rosa García-Merino; Ricardo Ocaña-Riola; Lorena Aguilar-Cano; Jennifer Valdellós; Inmaculada Bellido-Estévez; Gabriel Ariza-Zafra
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

8.  Impact of Geriatric Pharmacy Specialist Interventions to Reduce Potentially Inappropriate Medication Among Hospitalized Elderly Patients at Medical Wards: A Prospective Quasi-Experimental Study.

Authors:  Wajanakorn Chivapricha; Varalak Srinonprasert; Thanarat Suansanae
Journal:  Drugs Real World Outcomes       Date:  2020-10-15

9.  The effects of in-hospital deprescribing on potential prescribing omission in hospitalized elderly patients with polypharmacy.

Authors:  Miho Kaminaga; Junpei Komagamine; Shinpei Tatsumi
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.379

10.  Functionality and Outcome in Older Patients with Severe Aortic Stenosis (FOOPAS): an interdisciplinary study concept for a prospective trial.

Authors:  Ferdinand Vogt; Susanne Wicklein; Markus Gosch; Jürgen Jessl; Wolfgang Hitzl; Theodor Fischlein; Matthias Pauschinger; Steffen Pfeiffer; Dennis Eckner
Journal:  Clin Interv Aging       Date:  2018-02-01       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.